Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on July 16, 2007

Hypertension. 2007
Published online before print July 16, 2007, doi: 10.1161/HYPERTENSIONAHA.107.088534
A more recent version of this article appeared on September 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/3/481    most recent
HYPERTENSIONAHA.107.088534v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costello-Boerrigter, L. C.
Right arrow Articles by Burnett, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costello-Boerrigter, L. C.
Right arrow Articles by Burnett, J. C., Jr
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*SODIUM
Related Collections
Right arrow Structure
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Animal models of human disease
Right arrowRelated Article

Submitted on February 5, 2007
Revised on March 8, 2007

Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction

Lisa C. Costello-Boerrigter*; Guido Boerrigter; Gail J. Harty; Alessandro Cataliotti; Margaret M. Redfield; and John C. Burnett Jr

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minn.

* To whom correspondence should be addressed. E-mail: Costello.Lisa{at}mayo.edu.

Abstract--Unlike healthy subjects, overt congestive heart failure cannot "escape" the sodium- and water-retaining actions of mineralocorticoid excess. It is undefined whether escape occurs in asymptomatic left ventricular dysfunction (ALVD), which is characterized by preserved sodium homeostasis, natriuretic peptide activation, and normal circulating aldosterone. We hypothesized that, in ALVD, mineralocorticoid excess with exogenous deoxycorticosterone acetate (DOCA) would overwhelm renal compensatory mechanisms, resulting in sodium and water retention, and promote renal and cardiac collagen deposition. ALVD was induced in 2 groups (N=5 each) of dogs by tachypacing at 180 bpm. Urine was collected daily and blood drawn at baseline and days 2, 5, 8, and 11. One group served as control (ALVD), and the other received DOCA (ALVD+DOCA) starting at day 2 of pacing. Urine flow and sodium excretion were unchanged in the ALVD group. In ALVD+DOCA, urine flow and sodium excretion decreased on the first 2 days DOCA was given but normalized starting day 4. Urine flow and urinary cGMP excretion increased in ALVD+DOCA after DOCA escape. Plasma atrial natriuretic peptide, B-type natriuretic peptide, and cGMP increased equally in both groups. There were no differences in cardiorenal and hemodynamic parameters in an acute study on day 11. Although renal collagen area fraction was similar, left ventricular collagen area fraction in ALVD+DOCA was significantly higher than in ALVD (3.3±0.4% versus 2.0±0.2%; P=0.012). We conclude that ALVD can escape the sodium- and water-retaining effects of mineralocorticoid excess. Despite renal escape, increased left ventricular collagen deposition suggests that the heart but not the kidney failed to escape the tissue effects of DOCA.


Key words: basic science • experimental models • extracellular matrix • heart failure • kidney physiology/pathophysiology • mineralocorticoids


Related Article:

Promise of Mineralocorticoid Receptor Blockade in Asymptomatic Left Ventricular Dysfunction
Bertram Pitt
Hypertension 2007 50: 461-462. [Full Text] [PDF]



This article has been cited by other articles:


Home page
HypertensionHome page
B. P. Shapiro, T. E. Owan, S. Mohammed, M. Kruger, W. A. Linke, J. C. Burnett Jr, and M. M. Redfield
Mineralocorticoid Signaling in Transition to Heart Failure With Normal Ejection Fraction
Hypertension, February 1, 2008; 51(2): 289 - 295.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. Pitt
Promise of Mineralocorticoid Receptor Blockade in Asymptomatic Left Ventricular Dysfunction
Hypertension, September 1, 2007; 50(3): 461 - 462.
[Full Text] [PDF]